There were no significant differences in baseline characteristics between the groups except from the year of treatment, which exhibited a strong trend towards NHA treatment over time, unsurprisingly considering the approval process (Table 1 ).
← all excerpts
Novel hormonal agents in men with metastatic castration resistant prostate cancer and reduced performance status: Experiences of a specialized single center.
1
—
—